Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab

Acta Dermato-Venereologica

Volumn 91, Issue 1, 2011, Pages 70-71

  Brunasso, Alexandra Maria Giovanna ^a,b   Massone, Cesare ^c  

^a Departments of Environmental Dermatology and Venereology   (Austria)

^b GALLIERA HOSPITAL   (Italy)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLIXIMAB; METHOTREXATE; PLACEBO;

ANAPHYLACTIC SHOCK; ARTHRALGIA; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FOLLOW UP; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; NEOPLASM; PERIPHERAL NEUROPATHY; PERSONAL EXPERIENCE; PNEUMOCOCCAL INFECTION; PREGNANCY; PRIORITY JOURNAL; PRURITUS; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SMOKING; SUPPURATIVE HIDRADENITIS; SWELLING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; HIDRADENITIS SUPPURATIVA; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78751554505     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0989     Document Type: Letter

References (16)

1. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
2. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative? Br J Dermatol 2008; 159: 761-763.
3. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007; 32: 204-205.
4. Benitez-Macias JF, Garcia-Gil D, Brun-Romero FM. Fatal pneumococcal sepsis in patient with hidradenitis suppurative treated with infliximab. Med Clin 2008; 131: 799.
5. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217.
6. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-628.
7. Pedraz J, Dauden E, Perez-Gala S, Goiriz-Valdes R, Fernandez- Penas P, Garcia-Diaz A. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr 2007; 98: 325-331.
8. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007; 46: 1287-1291.
9. Antonucci A, Negosanti M, Negosanti L, Iozzo I, Varotti C. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm Venereol 2008; 88: 274-275.
10. Elkjaer M, Dinesen L, Benazzato L, Rodriquez J, Løgager V, Munkholm P. Efficacy of infl{ligature}iximab treatment in patients with severe fi{ligature}stulizing hidradenitis suppurativa. J Crohn's Colitis 2008; 2 241-245.
11. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7: 323-326.
12. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infl{ligature}iximab. Arthritis Rheum 2006; 54: 3782-3789.
13. Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: S73-77.
14. Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 2002; 47: 280-285.
15. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebocontrolled trial. J Am Acad Dermatol 2004; 51: 534-542.
16. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003; 149: 211-213.